Veeva Systems and OpenEvidence have announced a long-term partnership to co-develop Open Vista, a new artificial intelligence (AI) platform aimed at improving clinical trial access, accelerating drug discovery, and enhancing real-world adoption of existing medicines.

Open Vista will combine Veeva’s life sciences data and software infrastructure with OpenEvidence’s AI technology, which is already used by a large proportion of US physicians to support clinical decision-making. The companies said the new collaboration will focus on increasing patient access to clinical trials and enabling a deeper understanding of unmet medical needs across therapy areas.

Daniel Nadler, CEO of OpenEvidence, said: “OpenEvidence has become an accelerator for the dissemination of medical knowledge, with more than 40% of US physicians actively using its point-of-care clinical decision support AI. By bridging the gap between peer-reviewed evidence and on-the-ground medical practice, OpenEvidence is streamlining and quickening the translation of medical research from bench to bedside.

“For many patients with serious illnesses who have exhausted first and second line therapies, clinical trials are their most promising form of healthcare. In partnering with Veeva, we now have a unique opportunity to go a step further and leverage the power of AI to connect physicians and patients to relevant clinical trials and cutting-edge therapies.”

Veeva CEO Peter Gassner added: “We are very excited about our long-term partnership with OpenEvidence as we enter the AI chapter in life sciences. Combining the strengths of Veeva and OpenEvidence, we can use AI to bridge life sciences companies making life-saving medicines, patients, and the physicians who treat them. With Open Vista our aim is to help life sciences companies accelerate the development of effective new treatments, enable more patients to participate in clinical trials, and advance the understanding and adoption of existing medicines for better patient outcomes.”

Both companies expect the first Open Vista products to be released in 2026. The collaboration underscores growing industry momentum to integrate AI into clinical development and medical practice, a trend aimed at reducing research timelines and improving patient access to innovative therapies.